X7 Research - Full-service Contract Research Organization

What X7 Research - Full-service Contract Research Organization does

X7 Research (legal name: Экс Севен Ресеч / Eks Seven Resetch) is a privately-held, full-service Contract Research Organization headquartered in Saint Petersburg, Russia, providing integrated clinical research and pharmaceutical regulatory services since 2010. The company delivers five core service lines — registration strategy and consulting, clinical trials (Phase I–IV, bioequivalence, therapeutic equivalence, medical device trials), registration dossier preparation and EAEU compliance, post-authorization studies (Phase IV, non-interventional, investigator-initiated, PASS), and pharmacovigilance (QPPV provision, system audits, safety monitoring) — to pharmaceutical sponsors and medical organizations operating across Russia, the EAEU, CIS, and EU markets. Customer segments include local pharmaceutical companies requiring full-service CRO support and international Big Pharma firms seeking EAEU regulatory entry, alongside investigator-initiated study sponsors.

X7 Research's technology stack centers on a proprietary electronic Case Report Form (eCRF / эИРК) platform, validated clinical trial databases, automated data validation scripts, centralized remote monitoring aligned with FDA risk-based monitoring guidance, and ALCOA+ compliant data management processes including MedDRA/WHODrug/ATX medical coding. The company also operates a professional training and certification division offering free GCP courses and certified qualification programs developed in partnership with Sechenov University, functioning both as a talent pipeline and a marketing channel.

X7 Research generates revenue through fee-for-service professional services contracts on a project basis, with pricing determined by scope, complexity, and regulatory requirements rather than disclosed standard rate cards. GTM is sales-led and relationship-driven, executed through direct outreach to pharmaceutical sponsors, industry conferences, published white papers and publications, professional webinars, and referrals within the pharmaceutical and CRO ecosystem. The company employs a dedicated Business Development function and maintains active corporate social media presence on LinkedIn, VK, and YouTube. With 15+ years of continuous operation, no disclosed external funding, and a founder-owned ownership structure, X7 Research appears to be a stable, regionally entrenched mid-market CRO rather than a venture-backed scale player.

Name

X7 Research - Full-service Contract Research Organization

Legal name

Экс Севен Ресеч (X7 Research)

Website

https://x7cpr.com

Company type

Private

Founded year

2010

Operating status

Operating

Short description

X7 Research is a privately-held full-service Contract Research Organization (CRO) founded in 2010 and headquartered in Saint Petersburg, Russia. It provides clinical trials, pharmacovigilance, regulatory registration, and consulting services to local pharmaceutical companies and Big Pharma sponsors across Russia, EAEU, CIS, and EU markets.

Ownership category

akta.pro rank

Product category

Contract Research Services (Clinical Research Organization)

NAICS

Scientific Research and Development Services (5417), Other Scientific and Technical Consulting Services (54169)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Management Consulting Services (8742)

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

akta.pro secondary industries

Investigator & Site Training / GCP Support (HLAGACAF), Clinical Quality Assurance (GCP QA, TMF/QMS oversight) (HLAGAKAI), Medical Writing & Regulatory Submission Support CROs (HLAGAAAG), Clinical Data Management, Biostatistics & Statistical Programming CROs (HLAGAAAF)

Keywords

• Contract research services
• Clinical trial management
• Pharmacovigilance services
• Regulatory affairs consulting
• Bioequivalence studies

Headquarters

HQ city

Saint Petersburg

HQ country

Russia

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Others

Revenue model

1. Contract Research Services (Professional Services): X7 Research generates revenue by providing fee-for-service professional CRO services on a project-by-project basis. Services include clinical trial design and management, pharmacovigilance, regulatory registration consulting, data management, bioequivalence studies, and post-authorization studies. Revenue is earned through contractual agreements with pharmaceutical companies, typically structured as service contracts with defined milestones, deliverables, and pricing.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

X7 Research is a full-service Contract Research Organization (CRO) providing end-to-end pharmaceutical research services across Russia, EAEU, CIS, and EU markets. Its core offering spans registration strategy and consulting, clinical trial management (Phase I-IV, bioequivalence, therapeutic equivalence, medical device trials), regulatory registration dossier preparation, post-authorization studies, and pharmacovigilance services including QPPV provision, system building, audits, and safety monitoring. The company supplements service delivery with a professional training division delivering GCP, GVP, and bioequivalence documentation qualification programs.

Product overview

X7 Research is a full-service Contract Research Organization (CRO) providing integrated pharmaceutical research services across Russia, the EAEU, CIS, and EU markets. The company's portfolio consists of five core service areas: (1) Registration Strategy and Consulting, covering regulatory strategy, budgeting, feasibility, vendor selection, and data analysis; (2) Clinical Trials Services, encompassing bioequivalence and therapeutic equivalence studies, medical device trials, patient home visits, monitoring, data management, and medical documentation; (3) Registration Services, including dossier audits, EAEU compliance, PIL user testing, XML conversion, and turnkey registration; (4) Post-Authorization Clinical Studies, covering Phase IV, non-interventional, investigator-initiated studies, and post-authorisation safety studies (PASS); and (5) Pharmacovigilance Services, including QPPV for the EAEU, system building, safety monitoring, audits, and medical device vigilance. Additionally, X7 Research offers a training and professional development division providing GCP courses, GVP courses, and specialized bioequivalence documentation programs developed in partnership with Sechenov University. The company has provided pharmacovigilance services since 2010 and serves both local pharmaceutical companies and international (Big Pharma) clients.

Differentiator

Problem solved

Functional benefit

Products and services

• Registration Strategy and Consulting
• Clinical Trials Services Full-service clinical trial management encompassing development of medical documentation and biostatistics, monitoring, data management, patient home visits, bioequivalence studies, therapeutic equivalence studies, and clinical trials of medical devices, conducted across Russia and the EAEU.
• Registration Services Comprehensive registration support including audit of registration dossiers, bringing dossiers into compliance with EAEU requirements, PIL readability user testing, translation of registration dossiers, turnkey registration, and conversion of registration dossiers into XML format.
• Post-Authorization Clinical Studies Post-marketing study services covering Phase IV clinical trials, non-interventional studies, investigator-initiated studies, post-authorisation safety studies (PASS), and marketing research conducted in Russia, EAEU, CIS, and EU markets.
• Pharmacovigilance Services Full spectrum pharmacovigilance services including QPPV in the EAEU, building pharmacovigilance systems, safety in clinical trials, pharmacovigilance audits, pharmacovigilance contact person services, and safety monitoring of medical devices.
• QPPV Services in the EAEU Qualified Person for Pharmacovigilance services enabling pharmaceutical companies to meet EAEU pharmacovigilance requirements, including routine PV activities, PV system updates, and PSUR/DSUR/RMP preparation and submission.
• Bioequivalence Study Services Design, planning, and conduct of bioequivalence studies in compliance with EAEU requirements and Russian legislation, as part of registration or post-authorization obligations for generic and biosimilar pharmaceutical products.
• Therapeutic Equivalence Studies Design and conduct of therapeutic equivalence studies for pharmaceutical products, supporting registration and regulatory compliance in Russia and EAEU markets.
• Medical Device Clinical Trials Clinical trial management services for medical devices in compliance with applicable EAEU and Russian regulatory requirements.
• Post-Authorisation Safety Study (PASS) Post-authorisation safety study services covering quantification of risks, assessment of long-term drug safety, effectiveness of risk minimization measures, and regulatory reporting obligations. X7 Research supports all study stages from documentation development to regulatory submission.
• Pharmacovigilance Audit Auditing of pharmacovigilance systems for compliance with EAEU Good Pharmacovigilance Practice (GVP) requirements, identifying gaps and recommending corrective actions.
• Safety Monitoring of Medical Devices Vigilance and safety monitoring services for medical devices in compliance with EAEU rules for monitoring the safety, quality, and effectiveness of medical devices.
• PIL Readability User Testing User testing of Package Information Leaflets (PIL) in compliance with EAEU Decision No. 88 (Annex 14) requirements, including participant recruitment, questionnaire development, testing conduct, and report preparation for inclusion in the registration dossier.
• Audit of the Registration Dossier Comprehensive audit and review of registration dossiers to ensure completeness, accuracy, and compliance with regulatory requirements for Russian and EAEU market authorization.
• Translation of Registration Dossier Professional translation of registration dossiers and related regulatory documentation into Russian and other languages for submission to EAEU and Russian regulatory authorities.
• Free Online GCP Course Free online training course on Good Clinical Practice (GCP) standards for professionals entering or working in the clinical research field.
• Professional Development Program: Good Clinical Practice Professional development and qualification program on Good Clinical Practice (GCP) standards, covering ICH GCP E6 R2 requirements and applicable Russian and EAEU regulations.
• Course: Good Pharmacovigilance Practice Training course on Good Pharmacovigilance Practice (GVP), covering EAEU GVP requirements, Russian pharmacovigilance regulations, and practical implementation of pharmacovigilance activities.
• Professional Development Program: Bioequivalence Clinical Trial Documentation Advanced qualification program covering bioequivalence clinical trial documentation, including study design, reference drug selection, sample size justification, pharmacokinetic sampling schedules, and comparative dissolution testing (CDT). Developed jointly by Sechenov University and X7 Research specialists.

Quantifiable outcome

• Successfully conducting clinical trials and pharmacovigilance operations across EAEU, CIS, and EU markets for 15+ years
• +2 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core and minor.

• Sechenov University (First Moscow State Medical University, I.M. Sechenov)coreStrategic or Co-development Partner · 7 October 2024X7 Research developed and delivers educational programs in collaboration with Sechenov University's Department of Industrial Pharmacy. The partnership produced a qualification program 'Documents of Bioequivalence Clinical Studies' (course dates: October 7-18, 2024; in-person session October 16-18, 2024), costing 69,000 RUB. The program was jointly designed by the university's faculty and X7 Research specialists. X7 Research also provides GCP training courses in partnership with the university. This collaboration serves both as a talent development initiative and a GTM/channel-building mechanism.
• Takeda PharmaceuticalsminorOthersTakeda Pharmaceuticals was mentioned as a participant/conference co-organizer alongside X7 Research and other organizations at the 8th Conference of the International Society for Evidence-Based Healthcare (EBHC), where disease registries and patient awareness initiatives were discussed. The relationship appears to be conference collaboration rather than a formal commercial partnership.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Synergy Research Group: Russia/CIS-focused CRO offering clinical operations, regulatory affairs, and pharmacovigilance services to local and international pharma — overlapping directly with X7's five core service areas in the same EAEU geographies.
• OCT Clinical Trials: Russian-headquartered full-service CRO providing Phase I-IV clinical trial management, bioequivalence, and regulatory services across EAEU/CIS — the most direct local competitor to X7 Research in scope, geography, and target customer base.
• Ergomed: Specialized CRO with strong pharmacovigilance and orphan/rare disease expertise — comparable on the PV/QPPV service line and increasingly on full-service clinical operations in Europe.

Broad incumbents

• PSI CRO: Privately-held global CRO with deep operations in CIS/Eastern Europe, offering full-service clinical development including bioequivalence — a comparable mid-size competitor with overlapping EAEU footprint.
• Worldwide Clinical Trials: Global mid-size CRO with established presence in CIS/Russia offering Phase I-IV clinical, bioequivalence, and PV services — broader portfolio than X7 but directly comparable on bioequivalence and EAEU regulatory work.
• IQVIA: World's largest CRO with full-service Phase I-IV, real-world evidence, and technology-enabled trial operations — competes with X7 for any Big Pharma global trial with Russia/EAEU sites.
• Parexel International: Large global CRO with extensive regulatory, clinical, and PV services across multiple jurisdictions including historically strong Russia/CIS presence — comparable on Big Pharma service delivery and regulatory expertise.
• ICON plc: Top-5 global CRO with full clinical, bioequivalence, and PV capabilities across Europe and CIS — competes with X7 for pan-regional sponsor work and sets pricing benchmarks.

Emerging players

• Clinipace Worldwide: Mid-market global CRO with technology-enabled trial management and emerging CIS/Eastern Europe footprint — comparable on full-service scope targeting mid-sized pharma sponsors.
• Pharm-Olam: Mid-size global CRO with established operations in Eastern Europe and CIS — comparable on Phase II-IV services, oncology/rare disease specialization, and regional service delivery model.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/channel/UCPVaupFsw7QTfDLHI2NaiiQ/featured
• LinkedInlinkedin.com/company/x7-research

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about X7 Research - Full-service Contract Research Organization